Disc Medicine (IRON) is back in focus after the FDA issued a Complete Response Letter for its lead EPP drug, bitopertin, asking for additional Phase 3 data and delaying the potential approval timeline ...
In most instances, getting more horsepower from your engine requires "leaning" on it with non-stock performance modifications. Higher compression ratios and bigger-lift camshafts produce increased ...
Disc Medicine Inc. Annual cash flow by MarketWatch. View IRON net cash flow, operating cash flow, operating expenses and cash dividends.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results